19:05 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome Mouse studies identified a macrocyclic Trypanosoma rhodesain inhibitor that could help treat African trypanosomiasis. Screening of a library of cysteine protease inhibitors, in vitro activity and parasite culture assays, and structure-based optimization of...
17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
13:36 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other molecule...
17:44 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome In vitro studies identified a vinyl ketone peptide-based inhibitor of Trypanosoma rhodesain, a cysteine protease from T. brucei rhodesiense, that could help treat African trypanosomiasis. Chemical synthesis and in vitro testing of peptide-based Michael...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Alvine, Immunogenics deal

Immunogenics’ ImmunogenX subsidiary acquired Alvine’s non-cash assets, including latiglutenase and three celiac disease patient-reported outcome tools. Latiglutenase is a combination of a cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) engineered...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB)

Infectious disease INDICATION: Clostridium In vitro and mouse studies suggest ebselen could be repurposed to treat Clostridium difficile infection (CDI). Screening of a small molecule library in an assay for binding to the cysteine protease domain of...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

ALV003: Phase IIb started

Alvine began the double-blind, placebo-controlled, dose-ranging, international Phase IIb CeliAction Study to evaluate oral ALV003 for 12 weeks in about 500 patients with celiac disease who are symptomatic despite attempting to follow a gluten-free diet....
07:00 , Oct 7, 2013 |  BioCentury  |  Strategy

Room for improvement

AbbVie Inc. has struck two deals for compounds that would compete with marketed products against the same targets, banking that partners Ablynx N.V. and Galapagos N.V. will be able to show their compounds produce better...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Alvine, AbbVie deal

Alvine granted AbbVie an exclusive option to acquire the company or its ALV003, which is in Phase II testing to treat celiac disease, under undisclosed terms. AbbVie will pay Alvine $70 million up front...
00:39 , May 15, 2013 |  BC Extra  |  Company News

Alvine grants AbbVie option for celiac compound

Alvine Pharmaceuticals Inc. (San Carlos, Calif.) granted AbbVie Inc. (NYSE:ABBV) an exclusive option to acquire the company or its ALV003, which is in Phase II testing to treat celiac disease, under undisclosed terms. AbbVie will...